伏诺拉生在幽门螺杆菌根除治疗中的应用  

Application of Vonoprazan in Helicobacter pylori eradication therapy

作　　者：李佳颖 霍丽娟[2] LI Jiaying;HUO Lijuan(The First Clinical Medical College of Shanxi Medical University,Taiyuan 030001;Department of Gastroenterology,the First Hospital of Shanxi Medical University,China)

机构地区：[1]山西医科大学第一临床医学院,山西太原030001 [2]山西医科大学第一医院消化内科

出　　处：《胃肠病学和肝病学杂志》2024年第9期1229-1232,共4页Chinese Journal of Gastroenterology and Hepatology

摘　　要：幽门螺杆菌(Helicobacter pylori,H.pylori)感染是常见的慢性细菌感染,与多种胃肠道疾病相关。国内外共识推荐H.pylori根除方案均以抑酸药为基础。伏诺拉生是一种新型抑酸药,其抑酸作用强于常用的质子泵抑制剂(proton pump inhibitors,PPI)。基于伏诺拉生方案根除H.pylori的效果不劣于PPI,且耐受性良好,其广泛应用有望进一步提高H.pylori根除率。本文从伏诺拉生用于H.pylori感染初治、复治,难治性H.pylori、青霉素过敏H.pylori感染的根治、伏诺拉生安全性等方面进行综述,旨在评估伏诺拉生在H.pylori感染根除治疗中的临床应用价值。Helicobacter pylori(H.pylori)infection is a common chronic bacterial infection associated with a variety of gastrointestinal diseases.Domestic and foreign consensus recommends that H.pylori eradication programs are based on acid inhibitors.Vonoprazan is a new type of acid inhibitor with a stronger acid inhibition than commonly used proton pump inhibitors(PPI).The eradication effect of H.pylori based on Vonoprazan program is not inferior to PPI,and it is well tolerated.Wide application of Vonoprazan program is expected to further improve the H.pylori eradication rate.This article reviewed the use of Vonoprazan for primary and secondary treatment of H.pylori infection,the eradication of refractory H.pylori and penicillin-allergic H.pylori infection,and the safety of Vonoprazan,aiming to evaluate the clinical application value of Vonoprazan in the eradication treatment of H.pylori infection.

关 键 词：伏诺拉生 幽门螺杆菌 P-CAB PPI 

分 类 号：R378[医药卫生—病原生物学]